Kymera Therapeutics (KYMR) PT Raised to $125 at JPMorgan
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Apple beats quarterly estimates for profit and revenue
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
- Goldman data shows hedge funds cut leverage at fastest pace since March
Tweet
Share
E-mailGet Alerts KYMR Hot Sheet
Price: $127.51 --0%
Rating Summary:
26 Buy, 4 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 10 | Down: 15 | New: 12
Rating Summary:
26 Buy, 4 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 10 | Down: 15 | New: 12
Join SI Premium – FREE
JPMorgan analyst Eric Joseph raised the price target on Kymera Therapeutics (NASDAQ: KYMR) to $125.00 (from $70.00) while maintaining a Overweight rating.
You May Also Be Interested In
- Kymera Therapeutics (KYMR) PT Raised to $170 at Barclays
- Jazz Pharmaceuticals (JAZZ) PT Raised to $310 at JPMorgan
- Kymera Therapeutics (KYMR) PT Raised to $132 at Brookline Capital Markets
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
